Nocion Therapeutics Secures $62M in Series B Funding

Nocion Therapeutics Raises $62M in Series B Financing Round to Advance Pain-Relieving Therapies

Clinical-stage biopharmaceutical company, Nocion Therapeutics, has secured $62 million in a Series B financing round, bringing the total funds raised by the company to $122 million. The funding round was led by Arkin Bio Capital and Monograph Capital, with participation from prominent new and existing investors, including Canaan Partners, F-Prime Capital, Mass General Brigham Ventures, Mission BioCapital, and Osage University Partners. As a result of the financing round, Pini Orbach, Ph.D., from Arkin Bio Capital, and Freddie Dear from Monograph Capital, will join Nocion’s Board of Directors.